OGT milestones
| 2013 | OGT releases new CytoSure microarray for cancer research |
| 2013 | OGT granted prostate cancer biomarker licence by the ICR |
| 2012 | OGT initiates strategic expansion with the opening of New York office. |
| 2012 | OGT launches the Genefficiency RNA Sequencing Service |
| 2012 | OGT forms Scientific Advisory Board chaired by Peter Rigby, Emeritus Professor of Developmental Biology at the Institute of Cancer Research. |
| 2012 | OGT awarded €3 million from prestigious EU clinical research grants to detect and characterise pathogenic infection in clinical samples |
| 2012 | CytoSure ISCA +SNP array launched for reliable copy number variation detection combined with accurate identification of loss of heterozygosity (LOH) and uniparental disomy (UPD) |
| 2012 |
OGT releases first in a new line of cancer microarrays |
| 2012 |
OGT signs licensing deal for colorectal cancer biomarkers |
| 2012 |
OGT launches optimised rare disease sequencing and analysis service |
| 2012 |
OGT founder Professor Sir Ed Southern awarded the MRC Millennium Medal |
| 2011 | CytoSure Molecular Testing Arrays and Panels launched to deliver reliable detection of DNA copy number changes for a range of molecular disorders |
| 2011 | Working with OGT, NHS targets genotyping for every cancer patient in the UK |
|
2011 |
CytoSure HT Genomic DNA Labelling Kit launched for faster, high-throughput sample processing |
|
2011 |
CytoSure ISCA Sample Tracking Spike-ins launched for easy identification of sample mix-up |
|
2011 |
Genefficiency Sequencing Services launched offering expert project design and data interpretation |
|
2010 |
CytoSure ISCA UPD array launched — the first ever array combining aCGH probes for enhanced CNV calling with SNP content for detection of uniparental disomy |
|
2010 |
OGT’s Biomarker Discovery team announce panel of biomarkers offering potential for significantly improved detection of prostate cancer |
|
2010 |
OGT’s Genefficiency microarray service awarded Agilent High Throughput Certified Service provider status |
|
2010 |
CytoSure Services launched — a dedicated microarray screening service for cytogenetic samples |
|
2010 |
OGT awarded ISO9001, demonstrating ongoing commitment to providing the highest quality solutions and customer service |
|
2010 |
OGT awarded ISO27001, highlighting commitment to information security and confidentiality |
|
2010 |
CytoSure ISCA arrays launched, providing a standardised, evidence-based array format for cytogenetic analysis |
|
2010 |
OGT's Genefficiency Genomic Services awarded 10,000 sample project investigating the relationship between structural variation and susceptibility to type 1 diabetes |
|
2009 |
Launch of CytoSure Genomic DNA Labelling Kit — optimised for high signal-to-noise ratios |
|
2009 |
OGT Genefficiency Genomic Services complete the world’ largest copy number variation study for the Wellcome Trust Case Control Consortium — 20,000 samples screened in less than 20 weeks |
|
2009 |
OGT acquire Sense Proteomic to enhance expertise in diagnostic biomarkers |
|
2009 |
OGT complement CytoSure portfolio with full automation options from SciGene |
|
2009 |
CytoSure DMD array launched, allowing accurate detection of Duchenne muscular dystrophy (DMD) and Becker’s muscular dystrophy (BMD) |
|
2008 |
OGT microarray service awarded Agilent Certified Service Provider status |
|
2008 |
CytoSure Syndrome Plus v2 and Chromosome X arrays launched |
|
2006 |
OGT launch the CytoSure range of arrays and analysis software dedicated to cytogenetic analysis |
|
2003 |
OGT provides its first complete microarray services |
|
1995 |
Professor Sir Edwin Southern founds Oxford Gene Technology (OGT) |
| 1991 | First licensing of DNA microarray patents |
Find out more
For more information about any OGT product or service, please contact us.